“Bimekizumab for the Treatment of Moderate to Severe Plaque Psoriasis with Scalp, Nail and Palmoplantar Involvement Through 52 Weeks: Post-Hoc Analysis from the BE VIVID Phase 3 Trial”, J of Skin, vol. 5, no. 1, p. s18, Jan. 2021, doi: 10.25251/skin.5.supp.18.